Summit Securities Group’s MacroGenics MGNX Stock Holding History

Summit Securities Group’s Portfolio MGNX Stock Details MGNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-124	Closed	-$200	–	1254
2025 Q4	$200	Buy	+124	New	+$195	﹤0.01%	966
2025 Q3	–	Sell	-2,157	Closed	-$2.61K	–	1231
2025 Q2	$2.61K	Buy	+2,157	New	+$3.13K	﹤0.01%	1013
2023 Q4	–	Sell	-363	Closed	-$2K	–	810
2023 Q3	$2K	Buy	+363	New	+$1.81K	﹤0.01%	510

Other funds holding MGNX

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Summit Securities Group's MGNX Position: Q1 2026 in Review

Summit Securities Group sold out of MacroGenics (MGNX) in Q1 2026, closing a stake of 124 shares — an estimated $200 sold.

Summit Securities Group first reported a position in MGNX in Q3 2023 and held it in 3 quarters. The position peaked at $2.61K in Q2 2025. 109 funds tracked by Wall St. Rank hold MGNX as of Q1 2026.

Summit Securities Group reported no remaining MacroGenics position as of Q1 2026 after selling out during the quarter.
Summit Securities Group sold 124 MacroGenics shares in Q1 2026, an estimated $200.
Summit Securities Group first reported a position in MacroGenics in Q3 2023 and held it in 3 quarters.
Summit Securities Group's MacroGenics position peaked at $2.61K in Q2 2025.
109 funds tracked by Wall St. Rank held MacroGenics as of Q1 2026.

Based on Summit Securities Group's 13F filing for Q1 2026, filed 30 Apr 2026.